Atea Pharmaceuticals (AVIR) Share-based Compensation (2019 - 2026)

Atea Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $16.3 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 134.9% year-over-year to $16.3 million in Q1 2026; TTM through Mar 2026 was $16.3 million, a 64.93% decrease from a year earlier, with the FY2025 full-year figure at $13.2 million, down 74.43% from the prior year.
• Share-based Compensation climbed to $16.3 million in Q1 2026 per AVIR's latest filing, from -$15.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $43.8 million in Q4 2022 and bottomed at -$15.6 million in Q4 2025.
• The 5-year median for Share-based Compensation is $12.5 million (2023), against an average of $13.7 million.
• Across the five-year window, Share-based Compensation surged 326.65% in 2023 and slumped 209.46% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $43.8 million in 2022, then slumped by 72.23% to $12.2 million in 2023, then gained by 17.6% to $14.3 million in 2024, then slumped by 209.46% to -$15.6 million in 2025, then surged by 204.33% to $16.3 million in 2026.
• Per Business Quant, the three latest AVIR Share-based Compensation figures stand at $16.3 million (Q1 2026), -$15.6 million (Q4 2025), and $15.9 million (Q3 2025).